Information  X 
Enter a valid email address

Diurnal Group PLC (DNL)

  Print      Mail a friend

Thursday 09 November, 2017

Diurnal Group PLC

Director Dealing and Issue of Equity

RNS Number : 1101W
Diurnal Group PLC
09 November 2017
 

9 November 2017

 

Diurnal Group plc

("Diurnal" or the "Company")

 

Director Dealing and Issue of Equity

 

On 8 November 2017, Diurnal issued a total of 109,296 new ordinary shares of 5 pence in the Company ("Shares") under the Diurnal Group plc Long Term Incentive Plan (the "Plan"), including 69,565 new Shares to persons discharging managerial responsibilities ("PDMR"):

 

PDMR

Total number of Shares issued

Nature of issuance

Martin Whitaker

69,565

Vesting of Deferred Bonus Award

 

The Shares issued were awarded on a deferred basis on 8 November 2016, as previously notified on 9 November 2016. Upon receipt of these shares, Martin Whitaker subsequently sold 33,650 ordinary shares to settle payment of all tax and NI requirements in relation to the award as set out in the notification below.

 

Issue of equity

 

Application has been made to AIM for the admission of the 109,296 new Shares, which is anticipated to occur at 8.00am on 15 November 2017.  The Company has also made application for admission to AIM at the same time of the following shares that have previously been duly issued and allotted but not admitted to trading: 110,000 new Shares issued on 12 April 2017 in respect of the exercise of options by a former employee at an exercise price of 43.77p per new Share; 10,791 new Shares issued on 7 September 2017 in respect of the vesting of shares to Mr John Goddard, NED of the Company, at a price of 5p per new Share (as announced on 7 September 2017); 100,000 new Shares issued on 21 September 2017 in respect of the exercise of options by a former director at an exercise price of 0.2p per new Share; and 29,000 new Shares issued on 21 September 2017 in respect of the exercise of options by an employee at an exercise price of 43.77p per new Share.

 

Following admission of the new Shares, the Company's total issued share capital will be 52,569,846 Ordinary Shares. Therefore, the total number of voting rights in the Company is 52,569,846. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them in accordance with the Market Abuse Regulations

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

 



Identification code

GB00BDB6Q760



b)

 

Nature of the transaction

 

Vesting of awards under the Diurnal Group plc Long Term Incentive Plan as follows:

 

EMI deferred bonus award over 9,730 ordinary shares.

 

Non-EMI deferred bonus award over 59,835 ordinary shares.

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




120p

9,730




120p

59,835







d)

 

Aggregated information




- Aggregated volume

69,565 ordinary shares



- Price

£83,478.00



e)

 

Date of the transaction

 

8 November 2017

f)

 

Place of the transaction

 

Off market

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

Martin Whitaker

2

 

Reason for the notification

 

a)

 

Position/status

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

Diurnal Group plc

b)

 

LEI

 

213800I2HNUNZN1LDH29

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary Shares of 5 pence each in Diurnal Group plc

 



Identification code

GB00BDB6Q760



b)

 

Nature of the transaction

 

Sale of 33,650 shares

 

c)

 

Price(s) and volume(s)







Price(s)

Volume(s)




134.7p per share

33,650







d)

 

Aggregated information




- Aggregated volume

33,650 ordinary shares



- Price

£45,326.55



e)

 

Date of the transaction

 

8 November 2017

f)

 

Place of the transaction

 

XLON

 

 

 

For further information, please visit www.diurnal.co.uk or contact:



Diurnal Group plc

+44 (0)20 3727 1000

Martin Whitaker, Chief Executive Officer


Richard Bungay, Chief Financial Officer




Numis Securities Ltd (Nominated Adviser)

+44 (0)20 7260 1000

Nominated Adviser: Michael Meade,  Paul Gillam, Freddie Barnfield


Corporate Broking: James Black




Panmure Gordon (UK) Limited (Joint Broker)

+44 (0) 20 7886 2500

Corporate Finance: Freddy Crossley / Duncan Monteith


Corporate Broking: Tom Salvesen




FTI Consulting

+44 (0)20 3727 1000

Simon Conway


Victoria Foster Mitchell


Notes to Editors

 

About Diurnal Group plc

Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.

 

For further information about Diurnal, please visit www.diurnal.co.uk

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFSIFAUFWSEFF

a d v e r t i s e m e n t